Institute of Hematology and Oncology, Department of Hematology, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Leuk Lymphoma. 2011 Nov;52(11):2064-8. doi: 10.3109/10428194.2011.591008. Epub 2011 Jun 27.
B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are regulators of normal B-cell development and survival. We investigated their role in chronic lymphocyticleukemia (CLL) by relating serum protein levels and CLL cell mRNA expression with clinical factors and disease progression. In patients with CLL, BAFF serum levels were significantly lower than in controls (0.64 ng/mL vs. 0.77 ng/mL, p = 0.014), and APRIL serum levels were significantly higher (4.10 ng/mL vs. 1.84 ng/mL, p = 0.041). CLL cells expressed BAFF and APRIL mRNA at lower levels than normal B-cells. Low BAFF serum levels were significantly correlated with a high blood lymphocyte count and advanced clinical stage, whereas APRIL levels were correlated with CD38 expression. In a multivariate analysis, the combined analysis of BAFF and APRIL serum levels emerged as an independent predictor of disease progression.
B 细胞激活因子 (BAFF) 和增殖诱导配体 (APRIL) 是正常 B 细胞发育和存活的调节剂。我们通过将血清蛋白水平和 CLL 细胞 mRNA 表达与临床因素和疾病进展相关联，研究了它们在慢性淋巴细胞白血病 (CLL) 中的作用。在 CLL 患者中，BAFF 血清水平明显低于对照组 (0.64ng/mL 对 0.77ng/mL，p=0.014)，APRIL 血清水平明显升高 (4.10ng/mL 对 1.84ng/mL，p=0.041)。CLL 细胞表达的 BAFF 和 APRIL mRNA 水平低于正常 B 细胞。低 BAFF 血清水平与高血淋巴细胞计数和晚期临床分期显著相关，而 APRIL 水平与 CD38 表达相关。在多变量分析中，BAFF 和 APRIL 血清水平的联合分析是疾病进展的独立预测因子。
